Research ExplorerPublicationsResidual low HDV viraemia is associated HDV RNA relapse afte...

Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

Standard

Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. / Bremer, Birgit; Anastasiou, Olympia; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G; Yalcin, Kendal; Akarca, Ulus S; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Lüth, Stefan; Papatheodoridis, George V; Radu, Monica; Idilman, Ramazan; Manns, Michael P; Cornberg, Markus; Yurdaydin, Cihan; Wedemeyer, Heiner.

In: LIVER INT, Vol. 41, No. 2, 02.2021, p. 295-299.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bremer, B, Anastasiou, O, Hardtke, S, Caruntu, FA, Curescu, MG, Yalcin, K, Akarca, US, Gürel, S, Zeuzem, S, Erhardt, A, Lüth, S, Papatheodoridis, GV, Radu, M, Idilman, R, Manns, MP, Cornberg, M, Yurdaydin, C & Wedemeyer, H 2021, 'Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study', LIVER INT, vol. 41, no. 2, pp. 295-299. https://doi.org/10.1111/liv.14740

APA

Bremer, B., Anastasiou, O., Hardtke, S., Caruntu, F. A., Curescu, M. G., Yalcin, K., Akarca, U. S., Gürel, S., Zeuzem, S., Erhardt, A., Lüth, S., Papatheodoridis, G. V., Radu, M., Idilman, R., Manns, M. P., Cornberg, M., Yurdaydin, C., & Wedemeyer, H. (2021). Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. LIVER INT, 41(2), 295-299. https://doi.org/10.1111/liv.14740

Vancouver

Bremer B, Anastasiou O, Hardtke S, Caruntu FA, Curescu MG, Yalcin K et al. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. LIVER INT. 2021 Feb;41(2):295-299. https://doi.org/10.1111/liv.14740

Bibtex

@article{8d6305c690554f2484691829c7bf7b7e,
title = "Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study",
abstract = "The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.",
author = "Birgit Bremer and Olympia Anastasiou and Svenja Hardtke and Caruntu, {Florin Alexandru} and Curescu, {Manuela G} and Kendal Yalcin and Akarca, {Ulus S} and Selim G{\"u}rel and Stefan Zeuzem and Andreas Erhardt and Stefan L{\"u}th and Papatheodoridis, {George V} and Monica Radu and Ramazan Idilman and Manns, {Michael P} and Markus Cornberg and Cihan Yurdaydin and Heiner Wedemeyer",
note = "{\textcopyright} 2020 The Authors. Liver International published by John Wiley & Sons Ltd.",
year = "2021",
month = feb,
doi = "10.1111/liv.14740",
language = "English",
volume = "41",
pages = "295--299",
journal = "LIVER INT",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

AU - Bremer, Birgit

AU - Anastasiou, Olympia

AU - Hardtke, Svenja

AU - Caruntu, Florin Alexandru

AU - Curescu, Manuela G

AU - Yalcin, Kendal

AU - Akarca, Ulus S

AU - Gürel, Selim

AU - Zeuzem, Stefan

AU - Erhardt, Andreas

AU - Lüth, Stefan

AU - Papatheodoridis, George V

AU - Radu, Monica

AU - Idilman, Ramazan

AU - Manns, Michael P

AU - Cornberg, Markus

AU - Yurdaydin, Cihan

AU - Wedemeyer, Heiner

N1 - © 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

PY - 2021/2

Y1 - 2021/2

N2 - The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.

AB - The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.

U2 - 10.1111/liv.14740

DO - 10.1111/liv.14740

M3 - SCORING: Journal article

C2 - 33217778

VL - 41

SP - 295

EP - 299

JO - LIVER INT

JF - LIVER INT

SN - 1478-3223

IS - 2

ER -